Cybin announces additional adelia milestone achievements

Toronto--(business wire)--cybin inc. (neo:cybn) (nyse american:cybn) (“cybin” or the “company”), a biotechnology company focused on progressing psychedelics to therapeutics™, is pleased to announce that adelia therapeutics inc. (“adelia”), a wholly-controlled subsidiary of cybin, has achieved the milestones identified as y2, q2 (i), (vi), y2, q3 (ii), year 2 q4 (i) and year 3 q1 (i), (ii), (iii) as contemplated by the terms of a contribution agreement dated december 4, 2020 (the “transaction ag
CYBN Ratings Summary
CYBN Quant Ranking